Alcohol Consumption And Male Erectile Dysfunction: An Unfounded Reputation For Risk? UroToday.com - The report, one of four published articles from a population-based cross-sectional study principally on male erectile dysfunction (ED), is based on the responses of 1,580 participants to questions on their alcohol drinking behaviour. To assess the effects of alcohol on erectile function was not the primary objective of the study.
Source: www.medicalnewstoday.comSpring allergy survival guide: When do you need to see the doctor? Written by Margot Carmichael Lester for UNC Health Care Spring is in the air, and so is a lot of annoying pollen. That means many North Carolinians are sniffling and sneezing as their eyes water and throats scratch. It’s estimated that one in five people suffers from allergic rhinitis. “The most common allergens right now are tree [...]
Source: feedproxy.google.comBiosite brand Triage Cardiac Panel Use of affected lots of the Triage Cardiac Panel may lead to false negative results, possibly resulting in missed or incorrect diagnosis.
Source: www.fda.govFun Express Water-based Face Paints for Children Nationwide recall of cosmetic items due to reports of skin reactions in children, including rashes, itchiness, burning sensation, and swelling.
Source: www.fda.govUrologist, J. Francois Eid, M.D., Lauds Improvements In Penile Prosthesis And Artificial Urinary Sphincter Technologies Dr. J. Francois Eid has performed more internal penile implant surgeries than anyone in the world and has built a reputation for excellence in the treatment of erectile dysfunction (ED).
Source: www.medicalnewstoday.comSciele Pharma, Inc. Announce Completion Of Patient Recruitment For Global Phase III Trial Of PSD502 For Premature Ejaculation Sciele Pharma, Inc., a Shionogi company, and Plethora Solutions Holdings PLC ("Plethora," AIM: PLE), today announced the completion of patient recruitment of the PSD502 registration program for the treatment of premature ejaculation (PE). The preliminary results from this North American study are expected in mid-year 2009. A parallel European Phase III study of PSD502 concluded successfully in November 2008 with a positive outcome that was both clinically and statistically significant.
Source: www.medicalnewstoday.comTarceva (erlotinib) Dear Healthcare Professional letter issued to warn about GI perforation, exfoliative skin conditions and corneal perforation/ulceration.
Source: www.fda.gov
# posted by Network @ 1:11 AM
